{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:06:21Z","timestamp":1786982781741,"version":"build-2736575974"},"reference-count":101,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T00:00:00Z","timestamp":1765411200000},"content-version":"vor","delay-in-days":10,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"The Training Program for Academic Leaders in the Health System of Pudong New Area, Shanghai","award":["PWRd2023-14"],"award-info":[{"award-number":["PWRd2023-14"]}]},{"name":"Health Scientific Research Project of Health Committee of Pudong New Area, Shanghai","award":["PW2023A-55"],"award-info":[{"award-number":["PW2023A-55"]}]},{"name":"Talents Training Program the Seventh People\u2019s Hospital, Shanghai University of Traditional Chinese Medicine","award":["BDX2022-01"],"award-info":[{"award-number":["BDX2022-01"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs R D"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s40268-025-00531-8","type":"journal-article","created":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T11:54:49Z","timestamp":1765454089000},"page":"289-307","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Omadacycline Pharmacokinetics: Characteristics, Contributing Factors, and Clinical Significance"],"prefix":"10.1007","volume":"25","author":[{"given":"Huan","family":"Sun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoli","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiuzhen","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiaoli","family":"Zhai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kourong","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,11]]},"reference":[{"issue":"6","key":"531_CR1","doi-asserted-by":"publisher","DOI":"10.4110\/in.2020.20.e47","volume":"20","author":"CS Park","year":"2020","unstructured":"Park CS, Kim SH, Lee CK. Immunotherapy of autoimmune diseases with nonantibiotic characteristics of tetracyclines. Immune Netw. 2020;20(6):e47. https:\/\/doi.org\/10.4110\/in.2020.20.e47.","journal-title":"Immune Netw"},{"issue":"3","key":"531_CR2","doi-asserted-by":"publisher","first-page":"C539","DOI":"10.1152\/ajpcell.00047.2010","volume":"299","author":"MO Griffin","year":"2010","unstructured":"Griffin MO, Fricovsky E, Ceballos G, Villarreal F. Tetracyclines: a pleitropic family of compounds with promising therapeutic characteristics. Review of the literature. Am J Physiol Cell Physiol. 2010;299(3):C539\u201348. https:\/\/doi.org\/10.1152\/ajpcell.00047.2010.","journal-title":"Am J Physiol Cell Physiol"},{"key":"531_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2023.175949","volume":"956","author":"J Li","year":"2023","unstructured":"Li J, Qin Y, Zhao C, Zhang Z, Zhou Z. Tetracycline antibiotics: potential anticancer drugs. Eur J Pharmacol. 2023;956:175949. https:\/\/doi.org\/10.1016\/j.ejphar.2023.175949.","journal-title":"Eur J Pharmacol"},{"key":"531_CR4","unstructured":"Tetracycline. In: Drugs and lactation database (LactMed\u00ae). Bethesda: National Institute of Child Health and Human Development; 2024."},{"issue":"4","key":"531_CR5","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-008334","volume":"12","author":"M Tone","year":"2024","unstructured":"Tone M, Iwahori K, Hirata M, Ueyama A, Tani A, Haruta JI, et al. Tetracyclines enhance antitumor T-cell immunity via the Zap70 signaling pathway. J Immunother Cancer. 2024;12(4):e008334. https:\/\/doi.org\/10.1136\/jitc-2023-008334.","journal-title":"J Immunother Cancer"},{"issue":"1","key":"531_CR6","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1186\/s12903-021-01615-y","volume":"21","author":"M Meng","year":"2021","unstructured":"Meng M, Chen Y, Ren H, Zhang Q, Chen S, Zhou X, et al. Effect of tetracyclines on pulpal and periodontal healing after tooth replantation: a systematic review of human and animal studies. BMC Oral Health. 2021;21(1):289. https:\/\/doi.org\/10.1186\/s12903-021-01615-y.","journal-title":"BMC Oral Health"},{"issue":"4","key":"531_CR7","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1038\/s41432-024-01031-5","volume":"25","author":"AL Amaral","year":"2024","unstructured":"Amaral AL, Herrera D, Lund B, Andrade SA. What is the science underpinning the prescription of antibiotics in dentistry? Evid Based Dent. 2024;25(4):196\u20137. https:\/\/doi.org\/10.1038\/s41432-024-01031-5.","journal-title":"Evid Based Dent"},{"issue":"5\u20136","key":"531_CR8","doi-asserted-by":"publisher","first-page":"e1353","DOI":"10.1093\/milmed\/usad417","volume":"189","author":"DV Zurawski","year":"2024","unstructured":"Zurawski DV, Serio AW, Black C, Pybus B, Akers KS, Deck DH, et al. A review of omadacycline for potential utility in the military health system for the treatment of wound infections. Mil Med. 2024;189(5\u20136):e1353\u201361. https:\/\/doi.org\/10.1093\/milmed\/usad417.","journal-title":"Mil Med"},{"issue":"9","key":"531_CR9","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1080\/17425255.2023.2261376","volume":"19","author":"C Cilloniz","year":"2023","unstructured":"Cilloniz C, Torres A. The pharmacokinetic evaluation of omadacycline (oral only dosing regimen) for the treatment of community-acquired bacterial pneumonia (CABP). Expert Opin Drug Metab Toxicol. 2023;19(9):569\u201376. https:\/\/doi.org\/10.1080\/17425255.2023.2261376.","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"531_CR10","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/j.ijid.2021.01.032","volume":"104","author":"A Torres","year":"2021","unstructured":"Torres A, Garrity-Ryan L, Kirsch C, Steenbergen JN, Eckburg PB, Das AF, et al. Omadacycline vs moxifloxacin in adults with community-acquired bacterial pneumonia. Int J Infect Dis. 2021;104:501\u20139. https:\/\/doi.org\/10.1016\/j.ijid.2021.01.032.","journal-title":"Int J Infect Dis"},{"issue":"3","key":"531_CR11","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1002\/jcph.814","volume":"57","author":"E Tzanis","year":"2017","unstructured":"Tzanis E, Manley A, Villano S, Tanaka SK, Bai S, Loh E. Effect of food on the bioavailability of omadacycline in healthy participants. J Clin Pharmacol. 2017;57(3):321\u20137. https:\/\/doi.org\/10.1002\/jcph.814.","journal-title":"J Clin Pharmacol"},{"issue":"10","key":"531_CR12","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1016\/S1473-3099(19)30275-0","volume":"19","author":"W O'Riordan","year":"2019","unstructured":"O\u2019Riordan W, Cardenas C, Shin E, Sirbu A, Garrity-Ryan L, Das AF, et al. Once-daily oral omadacycline versus twice-daily oral linezolid for acute bacterial skin and skin structure infections (OASIS-2): a phase 3, double-blind, multicentre, randomised, controlled, non-inferiority trial. Lancet Infect Dis. 2019;19(10):1080\u201390. https:\/\/doi.org\/10.1016\/S1473-3099(19)30275-0.","journal-title":"Lancet Infect Dis"},{"issue":"12","key":"531_CR13","doi-asserted-by":"publisher","first-page":"2637","DOI":"10.1007\/s40121-024-01057-3","volume":"13","author":"GD Rodriguez","year":"2024","unstructured":"Rodriguez GD, Warren N, Yashayev R, Chitra S, Amodio-Groton M, Wright K. Intravenous versus oral omadacycline or linezolid for acute bacterial skin and skin infections: a post hoc analysis of the OASIS trials. Infect Dis Ther. 2024;13(12):2637\u201348. https:\/\/doi.org\/10.1007\/s40121-024-01057-3.","journal-title":"Infect Dis Ther"},{"issue":"3","key":"531_CR14","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1007\/s40265-020-01257-4","volume":"80","author":"GG Zhanel","year":"2020","unstructured":"Zhanel GG, Esquivel J, Zelenitsky S, Lawrence CK, Adam HJ, Golden A, et al. Omadacycline: a novel oral and intravenous aminomethylcycline antibiotic agent. Drugs. 2020;80(3):285\u2013313. https:\/\/doi.org\/10.1007\/s40265-020-01257-4.","journal-title":"Drugs"},{"issue":"4","key":"531_CR15","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics12040761","volume":"12","author":"M Karvouniaris","year":"2023","unstructured":"Karvouniaris M, Almyroudi MP, Abdul-Aziz MH, Blot S, Paramythiotou E, Tsigou E, et al. Novel antimicrobial agents for Gram-negative pathogens. Antibiotics. 2023;12(4):761. https:\/\/doi.org\/10.3390\/antibiotics12040761.","journal-title":"Antibiotics"},{"issue":"4","key":"531_CR16","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1080\/14728214.2019.1685494","volume":"24","author":"A Liapikou","year":"2019","unstructured":"Liapikou A, Cilloniz C, Palomeque A, Torres T. Emerging antibiotics for community-acquired pneumonia. Expert Opin Emerg Drugs. 2019;24(4):221\u201331. https:\/\/doi.org\/10.1080\/14728214.2019.1685494.","journal-title":"Expert Opin Emerg Drugs"},{"issue":"Suppl. 1","key":"531_CR17","doi-asserted-by":"publisher","first-page":"S16","DOI":"10.1093\/cid\/ciz309","volume":"69","author":"KA Rodvold","year":"2019","unstructured":"Rodvold KA, Pai MP. Pharmacokinetics and pharmacodynamics of oral and intravenous omadacycline. Clin Infect Dis. 2019;69(Suppl. 1):S16-22. https:\/\/doi.org\/10.1093\/cid\/ciz309.","journal-title":"Clin Infect Dis"},{"issue":"2","key":"531_CR18","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02057-17","volume":"62","author":"JK Berg","year":"2018","unstructured":"Berg JK, Tzanis E, Garrity-Ryan L, Bai S, Chitra S, Manley A, et al. Pharmacokinetics and safety of omadacycline in subjects with impaired renal function. Antimicrob Agents Chemother. 2018;62(2):e02057-17. https:\/\/doi.org\/10.1128\/AAC.02057-17.","journal-title":"Antimicrob Agents Chemother"},{"issue":"12","key":"531_CR19","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1002\/phar.2185","volume":"38","author":"KE Barber","year":"2018","unstructured":"Barber KE, Bell AM, Wingler MJB, Wagner JL, Stover KR. Omadacycline enters the ring: a new antimicrobial contender. Pharmacotherapy. 2018;38(12):1194\u2013204. https:\/\/doi.org\/10.1002\/phar.2185.","journal-title":"Pharmacotherapy"},{"issue":"2","key":"531_CR20","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1128\/AAC.02465-15","volume":"60","author":"M Linkevicius","year":"2015","unstructured":"Linkevicius M, Sandegren L, Andersson DI. Potential of tetracycline resistance proteins to evolve tigecycline resistance. Antimicrob Agents Chemother. 2015;60(2):789\u201396. https:\/\/doi.org\/10.1128\/AAC.02465-15.","journal-title":"Antimicrob Agents Chemother"},{"issue":"7","key":"531_CR21","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00624-19","volume":"63","author":"AJ Lepak","year":"2019","unstructured":"Lepak AJ, Zhao M, Marchillo K, VanHecker J, Andes DR. In vivo pharmacodynamics of omadacycline against Staphylococcus aureus in the neutropenic murine thigh infection model. Antimicrob Agents Chemother. 2019;63(7):e00624-19. https:\/\/doi.org\/10.1128\/AAC.00624-19.","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"531_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2025.116711","volume":"111","author":"MD Huband","year":"2025","unstructured":"Huband MD, Fedler KA, Mendes RE, Sader HS, Anastasiou D, Serio AW, et al. Surveillance of omadacycline against 35,000 bacterial clinical isolates from the United States (2019\u20132023). Diagn Microbiol Infect Dis. 2025;111(3):116711. https:\/\/doi.org\/10.1016\/j.diagmicrobio.2025.116711.","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"Suppl. 1","key":"531_CR23","doi-asserted-by":"publisher","first-page":"S6","DOI":"10.1093\/cid\/ciz395","volume":"69","author":"JA Karlowsky","year":"2019","unstructured":"Karlowsky JA, Steenbergen J, Zhanel GG. Microbiology and preclinical review of omadacycline. Clin Infect Dis. 2019;69(Suppl. 1):S6-15. https:\/\/doi.org\/10.1093\/cid\/ciz395.","journal-title":"Clin Infect Dis"},{"issue":"3","key":"531_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2021.106377","volume":"58","author":"YL Lee","year":"2021","unstructured":"Lee YL, Ko WC, Lee WS, Lu PL, Chen YH, Cheng SH, et al. In-vitro activity of cefiderocol, cefepime\/zidebactam, cefepime\/enmetazobactam, omadacycline, eravacycline and other comparative agents against carbapenem-nonsusceptible Enterobacterales: results from the Surveillance of Multicenter Antimicrobial Resistance in Taiwan (SMART) in 2017\u20132020. Int J Antimicrob Agents. 2021;58(3):106377. https:\/\/doi.org\/10.1016\/j.ijantimicag.2021.106377.","journal-title":"Int J Antimicrob Agents"},{"issue":"6","key":"531_CR25","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics12060953","volume":"12","author":"TJ Stone","year":"2023","unstructured":"Stone TJ, Kilic A, Williamson JC, Palavecino EL. In vitro activity of omadacycline and comparator antibiotics against extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae urinary isolates. Antibiotics. 2023;12(6):953. https:\/\/doi.org\/10.3390\/antibiotics12060953.","journal-title":"Antibiotics"},{"issue":"6","key":"531_CR26","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02265-19","volume":"64","author":"BD VanScoy","year":"2020","unstructured":"VanScoy BD, Lakota EA, Conde H, McCauley J, Friedrich L, Steenbergen JN, et al. Pharmacokinetic-pharmacodynamic characterization of omadacycline against Haemophilus influenzae using a one-compartment in vitro infection model. Antimicrob Agents Chemother. 2020;64(6):e02265-19. https:\/\/doi.org\/10.1128\/AAC.02265-19.","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"531_CR27","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00047-18","volume":"62","author":"L Stapert","year":"2018","unstructured":"Stapert L, Wolfe C, Shinabarger D, Marra A, Pillar C. In vitro activities of omadacycline and comparators against anaerobic bacteria. Antimicrob Agents Chemother. 2018;62(4):e00047-18. https:\/\/doi.org\/10.1128\/AAC.00047-18.","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"531_CR28","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/s40121-018-0198-x","volume":"7","author":"SCJ Jorgensen","year":"2018","unstructured":"Jorgensen SCJ, Mercuro NJ, Davis SL, Rybak MJ. Delafloxacin: place in therapy and review of microbiologic, clinical and pharmacologic properties. Infect Dis Ther. 2018;7(2):197\u2013217. https:\/\/doi.org\/10.1007\/s40121-018-0198-x.","journal-title":"Infect Dis Ther"},{"issue":"1","key":"531_CR29","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofz514","volume":"7","author":"JP Horcajada","year":"2019","unstructured":"Horcajada JP, Salata RA, \u00c1lvarez-Sala R, Nitu FM, Lawrence L, Quintas M, et al. A phase 3 study to compare delafloxacin with moxifloxacin for the treatment of adults with community-acquired bacterial pneumonia (DEFINE-CABP). Open Forum Infect Dis. 2019;7(1):ofz514. https:\/\/doi.org\/10.1093\/ofid\/ofz514.","journal-title":"Open Forum Infect Dis"},{"issue":"2","key":"531_CR30","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1177\/10600280221089007","volume":"57","author":"KW Garey","year":"2023","unstructured":"Garey KW, Rose W, Gunter K, Serio AW, Wilcox MH. Omadacycline and Clostridioides difficile: a systematic review of preclinical and clinical evidence. Ann Pharmacother. 2023;57(2):184\u201392. https:\/\/doi.org\/10.1177\/10600280221089007.","journal-title":"Ann Pharmacother"},{"issue":"2","key":"531_CR31","doi-asserted-by":"publisher","DOI":"10.1128\/aac.01251-24","volume":"69","author":"J Jo","year":"2025","unstructured":"Jo J, Hu C, Horvath TD, Haidacher SJ, Begum K, Alam MJ, et al. Phase I trial comparing bile acid and short-chain fatty acid alterations in stool collected from human subjects treated with omadacycline or vancomycin. Antimicrob Agents Chemother. 2025;69(2):e0125124. https:\/\/doi.org\/10.1128\/aac.01251-24.","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"531_CR32","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1093\/infdis\/jiad537","volume":"229","author":"J Jo","year":"2024","unstructured":"Jo J, Hu C, Begum K, Wang W, Le TM, Agyapong S, et al. Fecal pharmacokinetics and gut microbiome effects of oral omadacycline versus vancomycin in healthy volunteers. J Infect Dis. 2024;229(1):273\u201381. https:\/\/doi.org\/10.1093\/infdis\/jiad537.","journal-title":"J Infect Dis"},{"issue":"5","key":"531_CR33","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1093\/infdis\/jiac324","volume":"227","author":"ND Budi","year":"2023","unstructured":"Budi ND, Godfrey JJ, Safdar N, Shukla SK, Rose WE. Efficacy of omadacycline or vancomycin combined with germinants for preventing Clostridioides difficile relapse in a murine model. J Infect Dis. 2023;227(5):622\u201330. https:\/\/doi.org\/10.1093\/infdis\/jiac324.","journal-title":"J Infect Dis"},{"issue":"15","key":"531_CR34","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1056\/NEJMoa2300220","volume":"389","author":"TL Holland","year":"2023","unstructured":"Holland TL, Cosgrove SE, Doernberg SB, Jenkins TC, Turner NA, Boucher HW, et al. Ceftobiprole for treatment of complicated Staphylococcus aureus bacteremia. N Engl J Med. 2023;389(15):1390\u2013401. https:\/\/doi.org\/10.1056\/NEJMoa2300220.","journal-title":"N Engl J Med"},{"issue":"2","key":"531_CR35","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.cmi.2024.06.006","volume":"31","author":"KL Bellis","year":"2025","unstructured":"Bellis KL, Dissanayake OM, Harrison EM, Aggarwal D. Community methicillin-resistant Staphylococcus aureus outbreaks in areas of low prevalence. Clin Microbiol Infect. 2025;31(2):182\u20139. https:\/\/doi.org\/10.1016\/j.cmi.2024.06.006.","journal-title":"Clin Microbiol Infect"},{"issue":"11","key":"531_CR36","doi-asserted-by":"publisher","first-page":"2813","DOI":"10.3390\/microorganisms11112813","volume":"11","author":"J Ramirez","year":"2023","unstructured":"Ramirez J, Furmanek S, Chandler TR, Wiemken T, Peyrani P, Arnold F, et al. Epidemiology of pneumococcal pneumonia in Louisville, Kentucky, and its estimated burden of disease in the United States. Microorganisms. 2023;11(11):2813. https:\/\/doi.org\/10.3390\/microorganisms11112813.","journal-title":"Microorganisms"},{"issue":"8","key":"531_CR37","doi-asserted-by":"publisher","first-page":"952","DOI":"10.18553\/jmcp.2023.22454","volume":"29","author":"TP Lodise","year":"2023","unstructured":"Lodise TP, Gunter K, Mu F, Gao E, Yang D, Yim E, et al. Real-world effectiveness of omadacycline and impact of unapproved omadacycline prescription claims among adult outpatients with community-acquired bacterial pneumonia or acute bacterial skin and skin structure infections. J Manag Care Spec Pharm. 2023;29(8):952\u201364. https:\/\/doi.org\/10.18553\/jmcp.2023.22454.","journal-title":"J Manag Care Spec Pharm"},{"key":"531_CR38","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.jhin.2024.12.010","volume":"157","author":"S G\u00f6pel","year":"2025","unstructured":"G\u00f6pel S, Guther J, Gladstone BP, Conzelmann N, Bunk S, Terzer T, et al. Drivers of extended spectrum \u03b2-lactamase (ESBL)-producing Enterobacterales colonization among residents of long-term health care facilities: a European multicentric prospective cohort study. J Hosp Infect. 2025;157:67\u201374. https:\/\/doi.org\/10.1016\/j.jhin.2024.12.010.","journal-title":"J Hosp Infect"},{"issue":"1","key":"531_CR39","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1038\/s41598-021-81315-3","volume":"11","author":"SH Subramanya","year":"2021","unstructured":"Subramanya SH, Bairy I, Metok Y, Baral BP, Gautam D, Nayak N. Detection and characterization of ESBL-producing Enterobacteriaceae from the gut of subsistence farmers, their livestock, and the surrounding environment in rural Nepal. Sci Rep. 2021;11(1):2091. https:\/\/doi.org\/10.1038\/s41598-021-81315-3.","journal-title":"Sci Rep"},{"key":"531_CR40","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.ebiom.2017.04.032","volume":"19","author":"R Zhang","year":"2017","unstructured":"Zhang R, Liu L, Zhou H, Chan EW, Li J, Fang Y, et al. Nationwide surveillance of clinical carbapenem-resistant Enterobacteriaceae (CRE) strains in China. EBioMedicine. 2017;19:98\u2013106. https:\/\/doi.org\/10.1016\/j.ebiom.2017.04.032.","journal-title":"EBioMedicine"},{"issue":"2","key":"531_CR41","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01487-17","volume":"62","author":"LA Bundrant","year":"2018","unstructured":"Bundrant LA, Tzanis E, Garrity-Ryan L, Bai S, Chitra S, Manley A, et al. Safety and pharmacokinetics of the aminomethylcycline antibiotic omadacycline administered to healthy subjects in oral multiple-dose regimens. Antimicrob Agents Chemother. 2018;62(2):e01487-17. https:\/\/doi.org\/10.1128\/AAC.01487-17.","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"531_CR42","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1007\/s40261-022-01119-9","volume":"42","author":"IM Leviton","year":"2022","unstructured":"Leviton IM, Amodio-Groton M. Omadacycline oral dosing and pharmacokinetics in community-acquired bacterial pneumonia and acute bacterial skin and skin structure infection. Clin Drug Investig. 2022;42(3):193\u20137. https:\/\/doi.org\/10.1007\/s40261-022-01119-9.","journal-title":"Clin Drug Investig"},{"issue":"9","key":"531_CR43","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01135-17","volume":"61","author":"MH Gotfried","year":"2017","unstructured":"Gotfried MH, Horn K, Garrity-Ryan L, Villano S, Tzanis E, Chitra S, et al. Comparison of omadacycline and tigecycline pharmacokinetics in the plasma, epithelial lining fluid, and alveolar cells of healthy adult subjects. Antimicrob Agents Chemother. 2017;61(9):e01135-17. https:\/\/doi.org\/10.1128\/AAC.01135-17.","journal-title":"Antimicrob Agents Chemother"},{"issue":"8","key":"531_CR44","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1080\/00498254.2016.1213465","volume":"47","author":"J Flarakos","year":"2017","unstructured":"Flarakos J, Du Y, Gu H, Wang L, Einolf HJ, Chun DY, et al. Clinical disposition, metabolism and in vitro drug-drug interaction properties of omadacycline. Xenobiotica. 2017;47(8):682\u201396. https:\/\/doi.org\/10.1080\/00498254.2016.1213465.","journal-title":"Xenobiotica"},{"issue":"4","key":"531_CR45","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1007\/s40262-019-00843-4","volume":"59","author":"KA Rodvold","year":"2020","unstructured":"Rodvold KA, Burgos RM, Tan X, Pai MP. Omadacycline: a review of the clinical pharmacokinetics and pharmacodynamics. Clin Pharmacokinet. 2020;59(4):409\u201325. https:\/\/doi.org\/10.1007\/s40262-019-00843-4.","journal-title":"Clin Pharmacokinet"},{"key":"531_CR46","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.869237","volume":"13","author":"H Yang","year":"2022","unstructured":"Yang H, Huang Z, Chen Y, Zhu Y, Cao G, Wang J, et al. Pharmacokinetics, safety and pharmacokinetics\/pharmacodynamics analysis of omadacycline in Chinese healthy subjects. Front Pharmacol. 2022;13:869237. https:\/\/doi.org\/10.3389\/fphar.2022.869237.","journal-title":"Front Pharmacol"},{"issue":"11","key":"531_CR47","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01650-20","volume":"64","author":"SJ Kovacs","year":"2020","unstructured":"Kovacs SJ, Ting L, Praestgaard J, Sunkara G, Sun H, Stein DS, et al. An open-label study of the impact of hepatic impairment on the pharmacokinetics and safety of single oral and intravenous doses of omadacycline. Antimicrob Agents Chemother. 2020;64(11):e01650-20. https:\/\/doi.org\/10.1128\/AAC.01650-20.","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"531_CR48","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics11040479","volume":"11","author":"LF Amann","year":"2022","unstructured":"Amann LF, Alraish R, Broeker A, Kaffarnik M, Wicha SG. Tigecycline dosing strategies in critically ill liver impaired patients. Antibiotics (Basel). 2022;11(4):479. https:\/\/doi.org\/10.3390\/antibiotics11040479.","journal-title":"Antibiotics (Basel)"},{"issue":"5","key":"531_CR49","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02083-18","volume":"63","author":"JS Overcash","year":"2019","unstructured":"Overcash JS, Bhiwandi P, Garrity-Ryan L, Steenbergen J, Bai S, Chitra S, et al. Pharmacokinetics, safety, and clinical outcomes of omadacycline in women with cystitis: results from a phase 1b study. Antimicrob Agents Chemother. 2019;63(5):e02083-18. https:\/\/doi.org\/10.1128\/AAC.02083-18.","journal-title":"Antimicrob Agents Chemother"},{"issue":"7","key":"531_CR50","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02263-19","volume":"64","author":"EA Lakota","year":"2020","unstructured":"Lakota EA, Van Wart SA, Trang M, Tzanis E, Bhavnani SM, Safir MC, et al. Population pharmacokinetic analyses for omadacycline using phase 1 and 3 data. Antimicrob Agents Chemother. 2020;64(7):e02263-19. https:\/\/doi.org\/10.1128\/AAC.02263-19.","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"531_CR51","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1007\/s40121-021-00587-4","volume":"11","author":"GJ Moran","year":"2022","unstructured":"Moran GJ, Chitra S, McGovern PC. Efficacy and safety of omadacycline versus linezolid in acute bacterial skin and skin structure infections in persons who inject drugs. Infect Dis Ther. 2022;11(1):517\u201331. https:\/\/doi.org\/10.1007\/s40121-021-00587-4.","journal-title":"Infect Dis Ther"},{"issue":"3","key":"531_CR52","doi-asserted-by":"publisher","DOI":"10.1128\/jb.00211-23","volume":"206","author":"A Kuzminov","year":"2024","unstructured":"Kuzminov A. Bacterial nucleoid is a riddle wrapped in a mystery inside an enigma. J Bacteriol. 2024;206(3):e0021123. https:\/\/doi.org\/10.1128\/jb.00211-23.","journal-title":"J Bacteriol"},{"issue":"5","key":"531_CR53","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1038\/s41579-022-00820-y","volume":"21","author":"EM Darby","year":"2023","unstructured":"Darby EM, Trampari E, Siasat P, Gaya MS, Alav I, Webber MA, et al. Molecular mechanisms of antibiotic resistance revisited. Nat Rev Microbiol. 2023;21(5):280\u201395. https:\/\/doi.org\/10.1038\/s41579-022-00820-y.","journal-title":"Nat Rev Microbiol"},{"issue":"9","key":"531_CR54","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a025361","volume":"6","author":"S Arenz","year":"2016","unstructured":"Arenz S, Wilson DN. Bacterial protein synthesis as a target for antibiotic inhibition. Cold Spring Harb Perspect Med. 2016;6(9):a025361. https:\/\/doi.org\/10.1101\/cshperspect.a025361.","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"3","key":"531_CR55","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1128\/AAC.01066-13","volume":"58","author":"MP Draper","year":"2014","unstructured":"Draper MP, Weir S, Macone A, Donatelli J, Trieber CA, Tanaka SK, et al. Mechanism of action of the novel aminomethylcycline antibiotic omadacycline. Antimicrob Agents Chemother. 2014;58(3):1279\u201383. https:\/\/doi.org\/10.1128\/AAC.01066-13.","journal-title":"Antimicrob Agents Chemother"},{"issue":"10","key":"531_CR56","doi-asserted-by":"publisher","first-page":"3812","DOI":"10.1073\/pnas.1216691110","volume":"110","author":"L Jenner","year":"2013","unstructured":"Jenner L, Starosta AL, Terry DS, Mikolajka A, Filonava L, Yusupov M, et al. Structural basis for potent inhibitory activity of the antibiotic tigecycline during protein synthesis. Proc Natl Acad Sci USA. 2013;110(10):3812\u20136. https:\/\/doi.org\/10.1073\/pnas.1216691110.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"24","key":"531_CR57","doi-asserted-by":"publisher","first-page":"6409","DOI":"10.1016\/j.bmc.2016.07.029","volume":"24","author":"SK Tanaka","year":"2016","unstructured":"Tanaka SK, Steenbergen J, Villano S. Discovery, pharmacology, and clinical profile of omadacycline, a novel aminomethylcycline antibiotic. Bioorg Med Chem. 2016;24(24):6409\u201319. https:\/\/doi.org\/10.1016\/j.bmc.2016.07.029.","journal-title":"Bioorg Med Chem"},{"issue":"6","key":"531_CR58","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24065777","volume":"24","author":"A Baran","year":"2023","unstructured":"Baran A, Kwiatkowska A, Potocki L. Antibiotics and bacterial resistance: a short story of an endless arms race. Int J Mol Sci. 2023;24(6):5777. https:\/\/doi.org\/10.3390\/ijms24065777.","journal-title":"Int J Mol Sci"},{"issue":"2","key":"531_CR59","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1128\/AAC.01242-13","volume":"58","author":"AB Macone","year":"2014","unstructured":"Macone AB, Caruso BK, Leahy RG, Donatelli J, Weir S, Draper MP, et al. In vitro and in vivo antibacterial activities of omadacycline, a novel aminomethylcycline. Antimicrob Agents Chemother. 2014;58(2):1127\u201335. https:\/\/doi.org\/10.1128\/AAC.01242-13.","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"531_CR60","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1186\/s12866-020-02019-8","volume":"20","author":"M Xiao","year":"2020","unstructured":"Xiao M, Huang JJ, Zhang G, Yang WH, Kong F, Kudinha T, et al. Antimicrobial activity of omadacycline in vitro against bacteria isolated from 2014 to 2017 in China, a multi-center study. BMC Microbiol. 2020;20(1):350. https:\/\/doi.org\/10.1186\/s12866-020-02019-8.","journal-title":"BMC Microbiol"},{"issue":"6","key":"531_CR61","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1016\/j.chom.2024.05.015","volume":"32","author":"A Abbas","year":"2024","unstructured":"Abbas A, Barkhouse A, Hackenberger D, Wright GD. Antibiotic resistance: a key microbial survival mechanism that threatens public health. Cell Host Microbe. 2024;32(6):837\u201351. https:\/\/doi.org\/10.1016\/j.chom.2024.05.015.","journal-title":"Cell Host Microbe"},{"key":"531_CR62","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2022.808744","volume":"13","author":"MU Anyanwu","year":"2022","unstructured":"Anyanwu MU, Nwobi OC, Okpala COR, Ezeonu IM. Mobile tigecycline resistance: an emerging health catastrophe requiring urgent one health global intervention. Front Microbiol. 2022;13:808744. https:\/\/doi.org\/10.3389\/fmicb.2022.808744.","journal-title":"Front Microbiol"},{"issue":"2","key":"531_CR63","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1093\/jac\/dkab409","volume":"77","author":"R Li","year":"2022","unstructured":"Li R, Jiang Y, Peng K, Wang Y, Wang M, Liu Y, et al. Phenotypic and genomic analysis reveals Riemerella anatipestifer as the potential reservoir of tet(X) variants. J Antimicrob Chemother. 2022;77(2):374\u201380. https:\/\/doi.org\/10.1093\/jac\/dkab409.","journal-title":"J Antimicrob Chemother"},{"key":"531_CR64","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.jgar.2024.08.014","volume":"39","author":"S Alimoghadam","year":"2024","unstructured":"Alimoghadam S, Eslami A, Alimoghadam R, Bahrami Mianrood I, Azizmohammad Looha M, Khodadadi S, et al. The frequency of AmpC overproduction, OprD downregulation and OprM efflux pump expression in Pseudomonas aeruginosa: a comprehensive meta-analysis. J Glob Antimicrob Resist. 2024;39:159\u201369. https:\/\/doi.org\/10.1016\/j.jgar.2024.08.014.","journal-title":"J Glob Antimicrob Resist"},{"key":"531_CR65","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2012.00408","volume":"3","author":"Y Morita","year":"2012","unstructured":"Morita Y, Tomida J, Kawamura Y. MexXY multidrug efflux system of Pseudomonas aeruginosa. Front Microbiol. 2012;3:408. https:\/\/doi.org\/10.3389\/fmicb.2012.00408.","journal-title":"Front Microbiol"},{"issue":"2","key":"531_CR66","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.diagmicrobio.2017.10.010","volume":"90","author":"MA Pfaller","year":"2018","unstructured":"Pfaller MA, Rhomberg PR, Huband MD, Flamm RK. Activity of omadacycline tested against Streptococcus pneumoniae from a global surveillance program (2014). Diagn Microbiol Infect Dis. 2018;90(2):143\u20137. https:\/\/doi.org\/10.1016\/j.diagmicrobio.2017.10.010.","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"9","key":"531_CR67","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1038\/s41564-019-0445-2","volume":"4","author":"T He","year":"2019","unstructured":"He T, Wang R, Liu D, Walsh TR, Zhang R, Lv Y, et al. Emergence of plasmid-mediated high-level tigecycline resistance genes in animals and humans. Nat Microbiol. 2019;4(9):1450\u20136. https:\/\/doi.org\/10.1038\/s41564-019-0445-2.","journal-title":"Nat Microbiol"},{"issue":"1","key":"531_CR68","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics14010063","volume":"14","author":"GV Sakalauskien\u0117","year":"2025","unstructured":"Sakalauskien\u0117 GV, Malcien\u0117 L, Stankevi\u010dius E, Radzevi\u010dien\u0117 A. Unseen enemy: mechanisms of multidrug antimicrobial resistance in Gram-negative ESKAPE pathogens. Antibiotics. 2025;14(1):63. https:\/\/doi.org\/10.3390\/antibiotics14010063.","journal-title":"Antibiotics"},{"key":"531_CR69","doi-asserted-by":"publisher","DOI":"10.1016\/j.micpath.2020.104389","volume":"147","author":"W Luo","year":"2020","unstructured":"Luo W, Qin H, Chen D, Wu M, Meng K, Zhang A, et al. The dose regimen formulation of tilmicosin against Lawsonia intracellularis in pigs by pharmacokinetic-pharmacodynamic (PK-PD) model. Microb Pathog. 2020;147:104389. https:\/\/doi.org\/10.1016\/j.micpath.2020.104389.","journal-title":"Microb Pathog"},{"issue":"11","key":"531_CR70","doi-asserted-by":"publisher","first-page":"2762","DOI":"10.1093\/jac\/dkae315","volume":"79","author":"A Wiesner","year":"2024","unstructured":"Wiesner A, Zagrodzki P, Gawalska A, Pa\u015bko P. Clinically important interactions of macrolides and tetracyclines with dietary interventions: a systematic review with meta-analyses. J Antimicrob Chemother. 2024;79(11):2762\u201391. https:\/\/doi.org\/10.1093\/jac\/dkae315.","journal-title":"J Antimicrob Chemother"},{"issue":"12","key":"531_CR71","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1007\/s40262-024-01440-w","volume":"63","author":"M Sanders","year":"2024","unstructured":"Sanders M, Hong E, Chung PS, Rao AP, Beringer P. Pharmacokinetics of omadacycline in adults with cystic fibrosis. Clin Pharmacokinet. 2024;63(12):1701\u20139. https:\/\/doi.org\/10.1007\/s40262-024-01440-w.","journal-title":"Clin Pharmacokinet"},{"issue":"1","key":"531_CR72","doi-asserted-by":"publisher","first-page":"e01784","DOI":"10.1128\/AAC.01784-16","volume":"61","author":"W Lin","year":"2016","unstructured":"Lin W, Flarakos J, Du Y, Hu W, He H, Mangold J, et al. Pharmacokinetics, distribution, metabolism, and excretion of omadacycline following a single intravenous or oral dose of 14C-omadacycline in rats. Antimicrob Agents Chemother. 2016;61(1):e01784-e1816. https:\/\/doi.org\/10.1128\/AAC.01784-16.","journal-title":"Antimicrob Agents Chemother"},{"issue":"9","key":"531_CR73","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1007\/s40262-019-00767-z","volume":"58","author":"MW McCarthy","year":"2019","unstructured":"McCarthy MW. Clinical pharmacokinetics and pharmacodynamics of eravacycline. Clin Pharmacokinet. 2019;58(9):1149\u201353. https:\/\/doi.org\/10.1007\/s40262-019-00767-z.","journal-title":"Clin Pharmacokinet"},{"key":"531_CR74","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2024.106713","volume":"195","author":"K Wang","year":"2024","unstructured":"Wang K, Zhu Y, Xu F, Liu L, Liu L, Shi M, et al. Evaluation of omadacycline dosing regimens in Chinese using population pharmacokinetic-pharmacodynamic analysis. Eur J Pharm Sci. 2024;195:106713. https:\/\/doi.org\/10.1016\/j.ejps.2024.106713.","journal-title":"Eur J Pharm Sci"},{"issue":"1","key":"531_CR75","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1177\/0091270010363477","volume":"51","author":"JM Korth-Bradley","year":"2011","unstructured":"Korth-Bradley JM, Baird-Bellaire SJ, Patat AA, Troy SM, B\u00f6hmer GM, Gleiter CH, et al. Pharmacokinetics and safety of a single intravenous dose of the antibiotic tigecycline in patients with cirrhosis. J Clin Pharmacol. 2011;51(1):93\u2013101. https:\/\/doi.org\/10.1177\/0091270010363477.","journal-title":"J Clin Pharmacol"},{"issue":"5","key":"531_CR76","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1213\/ane.0b013e3181683dd7","volume":"106","author":"RJ Litz","year":"2008","unstructured":"Litz RJ, Roessel T, Heller AR, Stehr SN. Reversal of central nervous system and cardiac toxicity after local anesthetic intoxication by lipid emulsion injection. Anesth Analg. 2008;106(5):1575\u20137. https:\/\/doi.org\/10.1213\/ane.0b013e3181683dd7.","journal-title":"Anesth Analg"},{"key":"531_CR77","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/14740338.2025.2467815","volume":"16","author":"YJ Chen","year":"2025","unstructured":"Chen YJ, Gao SY, Fu J, Qin ST, Kong MY, Zhang XH, et al. The efficacy and safety of omadacycline in treating acute bacterial infections: a meta-analysis of randomized controlled trials. Expert Opin Drug Saf. 2025;16:1\u201311. https:\/\/doi.org\/10.1080\/14740338.2025.2467815.","journal-title":"Expert Opin Drug Saf"},{"issue":"6","key":"531_CR78","doi-asserted-by":"publisher","first-page":"905","DOI":"10.3390\/biom13060905","volume":"13","author":"Y Dang","year":"2023","unstructured":"Dang Y, Ma C, Chen K, Chen Y, Jiang M, Hu K, et al. The effects of a high-fat diet on inflammatory bowel disease. Biomolecules. 2023;13(6):905. https:\/\/doi.org\/10.3390\/biom13060905.","journal-title":"Biomolecules"},{"issue":"13","key":"531_CR79","doi-asserted-by":"publisher","first-page":"2641","DOI":"10.3390\/nu14132641","volume":"14","author":"CB Ioni\u021b\u0103-M\u00eendrican","year":"2022","unstructured":"Ioni\u021b\u0103-M\u00eendrican CB, Ziani K, Mititelu M, Oprea E, Neac\u0219u SM, Moro\u0219an E, et al. Therapeutic benefits and dietary restrictions of fiber intake: a state of the art review. Nutrients. 2022;14(13):2641. https:\/\/doi.org\/10.3390\/nu14132641.","journal-title":"Nutrients"},{"issue":"1","key":"531_CR80","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1186\/s10194-023-01653-7","volume":"24","author":"B B\u0142aszczyk","year":"2023","unstructured":"B\u0142aszczyk B, Straburzy\u0144ski M, Wi\u0119ckiewicz M, Budrewicz S, Niemiec P, Staszkiewicz M, et al. Relationship between alcohol and primary headaches: a systematic review and meta-analysis. J Headache Pain. 2023;24(1):116. https:\/\/doi.org\/10.1186\/s10194-023-01653-7.","journal-title":"J Headache Pain"},{"issue":"1","key":"531_CR81","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/s13318-020-00651-3","volume":"46","author":"TL Hunt","year":"2021","unstructured":"Hunt TL, Tzanis E, Bai S, Manley A, Chitra S, McGovern PC. The effect of verapamil, a P-gp inhibitor, on the pharmacokinetics, safety, and tolerability of omadacycline in healthy adults: a phase I, open-label, single-sequence study. Eur J Drug Metab Pharmacokinet. 2021;46(1):85\u201392. https:\/\/doi.org\/10.1007\/s13318-020-00651-3.","journal-title":"Eur J Drug Metab Pharmacokinet"},{"issue":"3","key":"531_CR82","doi-asserted-by":"publisher","DOI":"10.1128\/spectrum.00542-22","volume":"10","author":"T Abbey","year":"2022","unstructured":"Abbey T, Vialichka A, Jurkovic M, Biagi M, Wenzler E. Activity of omadacycline alone and in combination against carbapenem-nonsusceptible Acinetobacter baumannii with varying minocycline susceptibility. Microbiol Spectr. 2022;10(3):e0054222. https:\/\/doi.org\/10.1128\/spectrum.00542-22.","journal-title":"Microbiol Spectr"},{"issue":"6","key":"531_CR83","doi-asserted-by":"publisher","DOI":"10.1128\/aac.01579-22","volume":"67","author":"K Fujiwara","year":"2023","unstructured":"Fujiwara K, Aono A, Asami T, Morimoto K, Kamada K, Morishige Y, et al. In vitro synergistic effects of omadacycline with other antimicrobial agents against Mycobacterium abscessus. Antimicrob Agents Chemother. 2023;67(6):e0157922. https:\/\/doi.org\/10.1128\/aac.01579-22.","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"531_CR84","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01703-21","volume":"66","author":"MJ Karau","year":"2022","unstructured":"Karau MJ, Schmidt-Malan SM, Cunningham SA, Mandrekar JN, Pritt BS, Keepers TR, et al. Activity of omadacycline in rat methicillin-resistant Staphylococcus aureus osteomyelitis. Antimicrob Agents Chemother. 2022;66(1):e0170321. https:\/\/doi.org\/10.1128\/AAC.01703-21.","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"531_CR85","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1038\/s41467-019-08733-w","volume":"10","author":"KT Schiessl","year":"2019","unstructured":"Schiessl KT, Hu F, Jo J, Nazia SZ, Wang B, Price-Whelan A, et al. Phenazine production promotes antibiotic tolerance and metabolic heterogeneity in Pseudomonas aeruginosa biofilms. Nat Commun. 2019;10(1):762. https:\/\/doi.org\/10.1038\/s41467-019-08733-w.","journal-title":"Nat Commun"},{"issue":"3","key":"531_CR86","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1016\/j.celrep.2015.12.056","volume":"14","author":"V Saini","year":"2016","unstructured":"Saini V, Cumming BM, Guidry L, Lamprecht DA, Adamson JH, Reddy VP, et al. Ergothioneine maintains redox and bioenergetic homeostasis essential for drug susceptibility and virulence of Mycobacterium tuberculosis. Cell Rep. 2016;14(3):572\u201385. https:\/\/doi.org\/10.1016\/j.celrep.2015.12.056.","journal-title":"Cell Rep"},{"issue":"2","key":"531_CR87","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.resmic.2011.10.009","volume":"163","author":"AG Tkachenko","year":"2012","unstructured":"Tkachenko AG, Akhova AV, Shumkov MS, Nesterova LY. Polyamines reduce oxidative stress in Escherichia coli cells exposed to bactericidal antibiotics. Res Microbiol. 2012;163(2):83\u201391. https:\/\/doi.org\/10.1016\/j.resmic.2011.10.009.","journal-title":"Res Microbiol"},{"issue":"3","key":"531_CR88","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1038\/s41579-021-00620-w","volume":"20","author":"EK Perry","year":"2022","unstructured":"Perry EK, Meirelles LA, Newman DK. From the soil to the clinic: the impact of microbial secondary metabolites on antibiotic tolerance and resistance. Nat Rev Microbiol. 2022;20(3):129\u201342. https:\/\/doi.org\/10.1038\/s41579-021-00620-w.","journal-title":"Nat Rev Microbiol"},{"issue":"7","key":"531_CR89","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1038\/s41579-025-01155-0","volume":"23","author":"M Ahmad","year":"2025","unstructured":"Ahmad M, Aduru SV, Smith RP, Zhao Z, Lopatkin AJ. The role of bacterial metabolism in antimicrobial resistance. Nat Rev Microbiol. 2025;23(7):439\u201354. https:\/\/doi.org\/10.1038\/s41579-025-01155-0.","journal-title":"Nat Rev Microbiol"},{"issue":"6684","key":"531_CR90","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1126\/science.adk8013","volume":"383","author":"KJY Wu","year":"2024","unstructured":"Wu KJY, Tresco BIC, Ramkissoon A, Aleksandrova EV, Syroegin EA, See DNY, et al. An antibiotic preorganized for ribosomal binding overcomes antimicrobial resistance. Science. 2024;383(6684):721\u20136. https:\/\/doi.org\/10.1126\/science.adk8013.","journal-title":"Science"},{"key":"531_CR91","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2020.577564","volume":"11","author":"Y Liu","year":"2020","unstructured":"Liu Y, Yang K, Zhang H, Jia Y, Wang Z. Combating antibiotic tolerance through activating bacterial metabolism. Front Microbiol. 2020;11:577564. https:\/\/doi.org\/10.3389\/fmicb.2020.577564.","journal-title":"Front Microbiol"},{"issue":"3","key":"531_CR92","doi-asserted-by":"publisher","DOI":"10.1128\/mbio.00480-22","volume":"13","author":"DA Kitzenberg","year":"2022","unstructured":"Kitzenberg DA, Lee JS, Mills KB, Kim JS, Liu L, V\u00e1zquez-Torres A, et al. Adenosine awakens metabolism to enhance growth-independent killing of tolerant and persister bacteria across multiple classes of antibiotics. MBio. 2022;13(3):e0048022. https:\/\/doi.org\/10.1128\/mbio.00480-22.","journal-title":"MBio"},{"issue":"3","key":"531_CR93","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2020.115129","volume":"98","author":"Y Yang","year":"2020","unstructured":"Yang Y, Bian L, Hang X, Yan C, Huang Y, Ye F, et al. In vitro activity of new tetracycline analogues omadacycline and eravacycline against clinical isolates of Helicobacter pylori collected in China. Diagn Microbiol Infect Dis. 2020;98(3):115129. https:\/\/doi.org\/10.1016\/j.diagmicrobio.2020.115129.","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"12","key":"531_CR94","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.1007\/s40121-024-01065-3","volume":"13","author":"W Gao","year":"2024","unstructured":"Gao W, Yang J, Zhang X, Tian L, Xu D, Xu S, et al. Omadacycline for diverse infections in China: a real-world analysis of efficacy and safety. Infect Dis Ther. 2024;13(12):2509\u201326. https:\/\/doi.org\/10.1007\/s40121-024-01065-3.","journal-title":"Infect Dis Ther"},{"issue":"6","key":"531_CR95","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofab136","volume":"8","author":"G Sakoulas","year":"2021","unstructured":"Sakoulas G, Eckburg PB, Amodio-Groton M, Manley A, Tzanis E, Das AF, et al. Clinical efficacy of patients with secondary bacteremia treated with omadacycline: results from phase 3 acute bacterial skin and skin structure infections and community-acquired bacterial pneumonia studies. Open Forum Infect Dis. 2021;8(6):ofab136. https:\/\/doi.org\/10.1093\/ofid\/ofab136.","journal-title":"Open Forum Infect Dis"},{"key":"531_CR96","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2023.1207534","volume":"10","author":"DX Wang","year":"2024","unstructured":"Wang DX, Xiao LX, Deng XY, Deng W. Omadacycline for the treatment of severe pneumonia caused by Chlamydia psittaci complicated with acute respiratory distress syndrome during the COVID-19 pandemic. Front Med. 2024;10:1207534. https:\/\/doi.org\/10.3389\/fmed.2023.1207534.","journal-title":"Front Med"},{"issue":"2","key":"531_CR97","doi-asserted-by":"publisher","DOI":"10.1128\/aac.01087-24","volume":"69","author":"TM File Jr","year":"2025","unstructured":"File TM Jr, Ramirez JA, Wilde AM. New perspectives on antimicrobial agents: omadacycline for community-acquired pneumonia, skin and soft tissue infections, and nontuberculous mycobacteria (focus on M. abscessus). Antimicrob Agents Chemother. 2025;69(2):e0108724. https:\/\/doi.org\/10.1128\/aac.01087-24.","journal-title":"Antimicrob Agents Chemother"},{"issue":"8","key":"531_CR98","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/j.clinthera.2024.06.014","volume":"46","author":"A Zhang","year":"2024","unstructured":"Zhang A, Sun Y, Zuo M, Wei H, Chen J, Zhao M, et al. Physiologically based pharmacokinetic model for predicting omadacycline pharmacokinetics and pharmacodynamics in healthy and hepatic impairment populations. Clin Ther. 2024;46(8):629\u201335. https:\/\/doi.org\/10.1016\/j.clinthera.2024.06.014.","journal-title":"Clin Ther"},{"issue":"12","key":"531_CR99","doi-asserted-by":"publisher","first-page":"2257","DOI":"10.1111\/imj.16071","volume":"53","author":"PR Ingram","year":"2023","unstructured":"Ingram PR, Jones EE, Allen B, Murray RJ, Keehner TJ, Whitmore TJ. Omadacycline therapy for Mycobacterium abscessus species infections. Intern Med J. 2023;53(12):2257\u201363. https:\/\/doi.org\/10.1111\/imj.16071.","journal-title":"Intern Med J"},{"issue":"1","key":"531_CR100","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1186\/s12879-024-09097-3","volume":"24","author":"W Liang","year":"2024","unstructured":"Liang W, Yin H, Chen H, Xu J, Cai Y. Efficacy and safety of omadacycline for treating complicated skin and soft tissue infections: a meta-analysis of randomized controlled trials. BMC Infect Dis. 2024;24(1):219. https:\/\/doi.org\/10.1186\/s12879-024-09097-3.","journal-title":"BMC Infect Dis"},{"key":"531_CR101","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.2217\/fmb-2016-0100","volume":"11","author":"S Villano","year":"2016","unstructured":"Villano S, Steenbergen J, Loh E. Omadacycline: development of a novel aminomethylcycline antibiotic for treating drug-resistant bacterial infections. Future Microbiol. 2016;11:1421\u201334. https:\/\/doi.org\/10.2217\/fmb-2016-0100.","journal-title":"Future Microbiol"}],"container-title":["Drugs in R&D"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40268-025-00531-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40268-025-00531-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40268-025-00531-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T13:36:16Z","timestamp":1767188176000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40268-025-00531-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":101,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["531"],"URL":"https:\/\/doi.org\/10.1007\/s40268-025-00531-8","relation":{},"ISSN":["1174-5886","1179-6901"],"issn-type":[{"value":"1174-5886","type":"print"},{"value":"1179-6901","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"22 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Huan Sun, Xiaoli Hou, Qiuzhen Zhu, Juan Liu, Qiaoli Zhai, and Kourong Shi have no conflicts of interest that are directly relevant to the content of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"For this type of study, ethics approval is not required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Data sharing is not applicable to this article as no datasets were generated or analyzed during the current study.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"HS: conceptualization, methodology, validation, formal analysis, writing (original draft). XH: conceptualization, methodology, validation, formal analysis, data curation. QZ: investigation, resources, writing (review editing). JL: project administration, supervision. QZ: project administration, supervision. KS: writing (review editing), funding acquisition, supervision.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}